Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq
Biodexa Pharmaceuticals (Nasdaq: BDRX) has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 for continued listing. This follows a notice of non-compliance received on August 27, 2024, and a subsequent exception granted by the Nasdaq Hearings Panel on October 14, 2024. The company will remain under a discretionary panel monitor through February 24, 2025, during which it must promptly report any events that could affect its Nasdaq compliance status.
Biodexa Pharmaceuticals (Nasdaq: BDRX) ha ripristinato con successo la conformità con il requisito di prezzo minimo di offerta di $1.00 per la continuazione della quotazione su Nasdaq. Questo segue un avviso di non conformità ricevuto il 27 agosto 2024 e una successiva eccezione concessa dal Panel di Audizione di Nasdaq il 14 ottobre 2024. La società rimarrà sotto la supervisione di un panel discrezionale fino al 24 febbraio 2025, durante il quale dovrà segnalare tempestivamente qualsiasi evento che possa influenzare il suo stato di conformità con Nasdaq.
Biodexa Pharmaceuticals (Nasdaq: BDRX) ha recuperado con éxito el cumplimiento del requisito de precio mínimo de oferta de $1.00 para la continuación de la cotización. Esto sigue a un aviso de incumplimiento recibido el 27 de agosto de 2024 y una excepción posterior concedida por el Panel de Audiencias de Nasdaq el 14 de octubre de 2024. La compañía permanecerá bajo la supervisión de un panel discrecional hasta el 24 de febrero de 2025, durante el cual deberá informar de manera oportuna sobre cualquier evento que pueda afectar su estado de cumplimiento con Nasdaq.
바이오덱사 제약(Biodexa Pharmaceuticals) (Nasdaq: BDRX)는 나스닥의 최소 입찰 가격 요구 사항인 $1.00에 대한 준수를 성공적으로 회복했습니다. 이는 2024년 8월 27일에 받았던 비준수 통지와 이후 2024년 10월 14일 나스닥 청문회 패널이 부여한 예외 조치에 따른 것입니다. 이 회사는 2025년 2월 24일까지 재량 패널의 모니터링을 받으며, 이 기간 동안 나스닥 준수 상태에 영향을 미칠 수 있는 사건을 신속히 보고해야 합니다.
Biodexa Pharmaceuticals (Nasdaq: BDRX) a réussi à retrouver sa conformité avec l'exigence de prix minimum d'offre de 1,00 $ pour une cotation continue. Cela fait suite à un avis de non-conformité reçu le 27 août 2024 et à une exception accordée par le panel d'auditions de Nasdaq le 14 octobre 2024. L'entreprise restera sous la surveillance d'un panel discrétionnaire jusqu'au 24 février 2025, période durant laquelle elle devra signaler rapidement tout événement pouvant affecter son statut de conformité avec Nasdaq.
Biodexa Pharmaceuticals (Nasdaq: BDRX) hat erfolgreich die Einhaltung des Mindestangebotspreises von $1,00 für die Fortführung der Liste bei Nasdaq wiederhergestellt. Dies folgt auf eine Mitteilung über die Nichteinhaltung, die am 27. August 2024 erhalten wurde, und eine daraufhin am 14. Oktober 2024 vom Nasdaq Hearings Panel gewährte Ausnahme. Das Unternehmen bleibt bis zum 24. Februar 2025 unter der Überwachung eines diskretionären Panels, währenddessen es umgehend über Ereignisse berichten muss, die seinen Nasdaq-Compliance-Status beeinträchtigen könnten.
- Regained Nasdaq listing compliance, avoiding potential delisting
- Maintained minimum bid price requirement of $1.00
- Company remains under Nasdaq monitoring through February 2025, indicating ongoing compliance risks
Insights
Regaining Nasdaq compliance removes a significant near-term risk for Biodexa Pharmaceuticals, preventing a potential delisting that could have severely impacted stock liquidity and institutional investment access. However, the company remains under panel monitoring until February 2025, indicating ongoing scrutiny of their compliance status.
The micro-cap biotech's ability to maintain the
While maintaining Nasdaq listing is positive for market accessibility and credibility, the discretionary monitoring period suggests continued vigilance is needed regarding the company's ability to sustain compliance requirements.
November 12, 2024
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)
Regains Compliance For Continued Listing on Nasdaq
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces
that the Company has been formally notified that the Nasdaq Hearings Panel (the “Panel”) of the Nasdaq Stock Market LLC (“Nasdaq”) determined that the Company has regained compliance with the
As previously disclosed, the Company received notice from Nasdaq on August 27, 2024, informing the Company that it was not in compliance with the Minimum Bid Price Requirement. On October 14, 2024, the Panel granted the Company’s request for an exception to demonstrate compliance with the Minimum Bid Price Requirement for continued listing through October 31, 2024. The Company remains subject to a discretionary panel monitor through February 24, 2025, and is required to provide prompt notification during this exception period of any significant events that occur during this time that may affect the Company’s compliance with Nasdaq requirements.
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Blader Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
FAQ
When did Biodexa Pharmaceuticals (BDRX) regain Nasdaq compliance?
What was the minimum bid price requirement that BDRX needed to meet for Nasdaq compliance?